David Stephen Shulman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteosarcoma | 4 | 2023 | 881 | 1.560 |
Why?
|
| Bone Neoplasms | 5 | 2020 | 2529 | 1.040 |
Why?
|
| Sarcoma | 5 | 2023 | 1897 | 0.970 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 167 | 0.760 |
Why?
|
| Receptor, trkA | 1 | 2020 | 164 | 0.680 |
Why?
|
| SEER Program | 2 | 2022 | 1508 | 0.670 |
Why?
|
| Nomograms | 1 | 2020 | 228 | 0.660 |
Why?
|
| Bacillus | 1 | 2018 | 77 | 0.650 |
Why?
|
| Neutropenia | 1 | 2018 | 895 | 0.450 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2021 | 5442 | 0.430 |
Why?
|
| Bacteremia | 1 | 2018 | 962 | 0.410 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 689 | 0.400 |
Why?
|
| Bone Marrow Transplantation | 1 | 2016 | 2765 | 0.320 |
Why?
|
| Neoplasms | 8 | 2021 | 21683 | 0.320 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 820 | 0.320 |
Why?
|
| Fever | 1 | 2015 | 1616 | 0.300 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 3597 | 0.290 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 1832 | 0.290 |
Why?
|
| Child | 16 | 2023 | 77709 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 11524 | 0.270 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 5535 | 0.260 |
Why?
|
| Antineoplastic Agents | 4 | 2020 | 13695 | 0.240 |
Why?
|
| Child, Preschool | 10 | 2021 | 41006 | 0.240 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 2957 | 0.210 |
Why?
|
| Retrospective Studies | 10 | 2023 | 77449 | 0.200 |
Why?
|
| Adolescent | 13 | 2023 | 85781 | 0.200 |
Why?
|
| Length of Stay | 1 | 2015 | 6309 | 0.200 |
Why?
|
| Patient Readmission | 1 | 2015 | 3114 | 0.190 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2020 | 26 | 0.190 |
Why?
|
| Minors | 1 | 2020 | 50 | 0.180 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2020 | 104 | 0.180 |
Why?
|
| Prognosis | 4 | 2022 | 29063 | 0.180 |
Why?
|
| Risk Assessment | 1 | 2020 | 23338 | 0.170 |
Why?
|
| Gene Fusion | 1 | 2022 | 371 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 323 | 0.170 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 13102 | 0.170 |
Why?
|
| Off-Label Use | 1 | 2020 | 169 | 0.170 |
Why?
|
| Biliary Atresia | 1 | 2019 | 73 | 0.160 |
Why?
|
| Ribonuclease III | 1 | 2020 | 275 | 0.160 |
Why?
|
| Vincristine | 1 | 2020 | 1039 | 0.160 |
Why?
|
| Leiomyosarcoma | 1 | 2022 | 477 | 0.150 |
Why?
|
| Industry | 1 | 2020 | 365 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 629 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 523 | 0.150 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 2016 | 7 | 0.150 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2020 | 375 | 0.150 |
Why?
|
| Facial Paralysis | 1 | 2021 | 338 | 0.150 |
Why?
|
| Herpesvirus 8, Human | 1 | 2019 | 258 | 0.150 |
Why?
|
| Blast Crisis | 1 | 2016 | 103 | 0.140 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 370 | 0.130 |
Why?
|
| Drug Approval | 2 | 2019 | 742 | 0.130 |
Why?
|
| Research Support as Topic | 1 | 2020 | 705 | 0.130 |
Why?
|
| Humans | 30 | 2023 | 744343 | 0.130 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 547 | 0.130 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 570 | 0.130 |
Why?
|
| Young Adult | 7 | 2023 | 56430 | 0.130 |
Why?
|
| Infant | 6 | 2021 | 35136 | 0.120 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 1584 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 39050 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2019 | 1533 | 0.100 |
Why?
|
| Adult | 11 | 2023 | 214055 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 895 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1061 | 0.100 |
Why?
|
| Medical Oncology | 2 | 2020 | 2265 | 0.100 |
Why?
|
| Remission Induction | 1 | 2016 | 2386 | 0.100 |
Why?
|
| Rural Health Services | 1 | 2014 | 379 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2020 | 6459 | 0.090 |
Why?
|
| Incidence | 3 | 2019 | 20947 | 0.090 |
Why?
|
| Bone Marrow | 1 | 2020 | 2948 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2951 | 0.090 |
Why?
|
| Time Factors | 4 | 2020 | 40075 | 0.090 |
Why?
|
| Genomics | 2 | 2023 | 5720 | 0.080 |
Why?
|
| Age Factors | 3 | 2020 | 18370 | 0.080 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 783 | 0.080 |
Why?
|
| Male | 12 | 2021 | 350118 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2019 | 2119 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1142 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 7913 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4803 | 0.070 |
Why?
|
| Female | 11 | 2021 | 380194 | 0.070 |
Why?
|
| Prevalence | 1 | 2023 | 15226 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2018 | 10252 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2020 | 63114 | 0.060 |
Why?
|
| United States | 4 | 2020 | 69872 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9239 | 0.060 |
Why?
|
| Risk Factors | 2 | 2022 | 72290 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2021 | 25625 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 2938 | 0.060 |
Why?
|
| Hypoaldosteronism | 1 | 2001 | 8 | 0.050 |
Why?
|
| Drug Dosage Calculations | 1 | 2020 | 114 | 0.040 |
Why?
|
| Renin | 1 | 2001 | 642 | 0.040 |
Why?
|
| Government | 1 | 2020 | 165 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 53288 | 0.040 |
Why?
|
| Ganciclovir | 1 | 2019 | 258 | 0.040 |
Why?
|
| Glioblastoma | 1 | 2013 | 3481 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2020 | 317 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 402 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2019 | 15295 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 780 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 707 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 1041 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 40561 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 1581 | 0.030 |
Why?
|
| Drug Industry | 1 | 2020 | 746 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1641 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 3508 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2013 | 205 | 0.030 |
Why?
|
| Medically Underserved Area | 1 | 2014 | 253 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 8863 | 0.030 |
Why?
|
| Rwanda | 1 | 2014 | 703 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 2016 | 0.030 |
Why?
|
| RNA | 1 | 2022 | 2749 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2019 | 1708 | 0.020 |
Why?
|
| Lymphoma | 1 | 2019 | 1877 | 0.020 |
Why?
|
| Morpholines | 1 | 2013 | 571 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2013 | 542 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2019 | 2240 | 0.020 |
Why?
|
| Biphenyl Compounds | 1 | 2013 | 913 | 0.020 |
Why?
|
| Middle Aged | 2 | 2020 | 213383 | 0.020 |
Why?
|
| Biopsy | 1 | 2020 | 6756 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2023 | 7729 | 0.020 |
Why?
|
| Health Resources | 1 | 2014 | 911 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10943 | 0.020 |
Why?
|
| Carcinoma | 1 | 2019 | 2375 | 0.020 |
Why?
|
| Boston | 1 | 2020 | 9313 | 0.020 |
Why?
|
| Risk | 1 | 2019 | 9687 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 3689 | 0.020 |
Why?
|
| Mutation | 2 | 2022 | 29786 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 11031 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 3557 | 0.020 |
Why?
|
| Registries | 1 | 2020 | 8089 | 0.020 |
Why?
|
| Research Design | 1 | 2020 | 5987 | 0.010 |
Why?
|
| Dysautonomia, Familial | 1 | 1985 | 95 | 0.010 |
Why?
|
| Liver | 1 | 2019 | 7474 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 3798 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13284 | 0.010 |
Why?
|
| Fludrocortisone | 1 | 2001 | 25 | 0.010 |
Why?
|
| Developing Countries | 1 | 2014 | 2815 | 0.010 |
Why?
|
| Fentanyl | 1 | 1985 | 410 | 0.010 |
Why?
|
| Pyridines | 1 | 2013 | 2825 | 0.010 |
Why?
|
| Mice | 2 | 2022 | 81183 | 0.010 |
Why?
|
| Health Personnel | 1 | 2014 | 3218 | 0.010 |
Why?
|
| Melanoma | 1 | 2019 | 5510 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2001 | 433 | 0.010 |
Why?
|
| Introns | 1 | 2001 | 991 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 1985 | 1171 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 16689 | 0.010 |
Why?
|
| Aldosterone | 1 | 2001 | 877 | 0.010 |
Why?
|
| Animals | 2 | 2022 | 168757 | 0.010 |
Why?
|
| Exons | 1 | 2001 | 2437 | 0.010 |
Why?
|
| Heterozygote | 1 | 2001 | 2804 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4751 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 1790 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 35421 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 23403 | 0.010 |
Why?
|
| Heart Rate | 1 | 1985 | 4091 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1985 | 8554 | 0.000 |
Why?
|